Ongoing Mesothelioma Clinical Trials

---

An Open-label, Multi-center, 2-arm Phase I/II Trial of LBY135 Alone and in Combination With Capecitabine in Advanced Solid Tumors. (10/3/06)

• Trial offered in: Nevada

---

Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours (7/25/06)

• Summary: To determine whether doses of 30 mg and 45 mg AZD2171 can be well tolerated without significant drug withdrawal when accompanied by a suitable hypertension management strategy or dose reduction

• Trial offered in:
  (Click the above link for contact information)

---

Vorinostat, Phase III Randomized Study of Vorinostat (SAHA) in Patients With Progressive or Relapsed Advanced Malignant Pleural Mesothelioma. Offered at Several Clinics Nationwide, Including UCLA Medical School in Los Angeles, California (Investigator Dr. Robert Cameron) (3/27/06)

• Summary: Compare the overall survival of patients with progressive or relapsed advanced malignant pleural mesothelioma treated with vorinostat (SAHA) vs placebo. Determine the overall safety and toxicity of vorinostat (SAHA) in these patients.

• Trial offered in: California, Maryland
  (Click the above link for contact information)

---

Suberoylanilide Hydroxamic Acid (SAHA) Versus Placebo in Advanced Malignant Pleural Mesothelioma (Last Updated November 4, 2005)

• Summary: Study to determine the safety, tolerability, and anti-tumor effectiveness of an oral investigational drug, suberoylanilide hydroxamic acid, in the treatment of advanced malignant pleural mesothelioma.

• Trial offered in: Nevada, Europe
  (Click the above link for contact information)

---

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma (Last Updated October, 2005)

• Summary: This randomized phase II trial is to see if combination chemotherapy works better with or without bevacizumab in treating patients who have malignant mesothelioma. (Summary Last Modified 10/6/2004)

• Trial offered in: California, Illinois, Indiana, Maryland, Massachusetts, New York, Pennsylvania, Texas, Wisconsin
  (Click the above link for contact information)

---

ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen (8/16/05)

• Summary: Randomized phase III trial comparing Onconase plus doxorubicin with doxorubicin alone in treating patients with malignant mesothelioma.

• Trial offered in: California, Colorado, Florida, Illinois, Indiana, New Jersey, New York, Texas, Virginia, Germany
  (Click the above link for contact information)

---

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma (Last Updated October, 2005)

• Summary: This randomized phase II trial is to see if combination chemotherapy works better with or without bevacizumab in treating patients who have malignant mesothelioma. (Summary Last Modified 10/6/2004)

• Trial offered in: California, Illinois, Indiana, Maryland, Massachusetts, New York, Pennsylvania, Texas, Wisconsin
  (Click the above link for contact information)

---

Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma (Last Updated October, 2005)

• Summary: Randomized phase III trial to compare the effectiveness of active symptom control with or without chemotherapy in treating patients who have malignant pleural mesothelioma.

• Trial offered in: United Kingdom, England
  (Click the above link for contact information)

---

Neoadjuvant Pemetrexed Disodium and Cisplatin Followed by Surgery and Radiation Therapy in Treating Patients With Pleural Mesothelioma (Last Updated September, 2005)

• Summary: Phase II Study of Neoadjuvant Pemetrexed Disodium and Cisplatin Followed By Extrapleural Pneumonectomy and Radiotherapy in Patients With Stage I, II, or III Pleural Mesothelioma

• Trial offered in: Massachusetts, New York
  (Click the above link for contact information)

---

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma (Last Updated August 25, 2005)

• Summary: To determine whether the combination of the investigational drugs Avastin and Tarceva are effective in patients with mesothelioma who have previously been treated with chemotherapy. Condition Intervention Phase Mesothelioma Drug: Erlotinib (Traveca, OSI-774) Drug: Bevacizumab (Avastin) Phase II

• Trial offered in: Massachusetts, Illinois
  (Click the above link for contact information)

---

Study Sorafenib in Treating Patients with Malignant Mesothelioma (7/28/05)

• Summary: To study how well sorafenib works in treating patients with malignant mesothelioma.

• Trial offered in: California, Delaware, Florida, Illinois, Indiana, Maryland, Minnesota, Missouri, New Jersey, New York, Ohio, Tennessee, Vermont, West Virginia
  (Click the above link for contact information)

---

BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors (4/8/05)

• Summary: To determine the optimum doses of BAY 43-9006 (Sorafenib) and bevacizumab (Avastin) that can be used safely in combination in patients with various solid tumor cancers.

• Trial offered in: Maryland
  (Click the above link for contact information)

---

A Double-Blind Placebo Controlled Randomized Phase II of Gemcitabine & Cisplatin With Or Without the VEGF Inhibitor Bevacizumab in Patients with Malignant Mesothelioma (8/3/04)

• Summary: To determine the effect on malignant mesothelioma of the investigational drug Bevacizumab as compared to placebo when added to gemcitabine and Cisplatin (a commonly used chemotherapy regimen for mesothelioma).

• Trial offered in: California
  (Click the above link for contact information)

---

PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma (7/19/04)

• Summary: Phase II trial to study the effectiveness of PTK787/ZK 222584 in treating patients with unresectable malignant mesothelioma.

• Trial offered in: Alabama, California, Delaware, District of Columbia, Florida Illinois, Indiana, Iowa, Kentucky, Maryland, Massachusetts Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania Rhode Island, Tennessee, Texas, Vermont, Virginia, West Virginia
  (Click the above link for contact information)

---

Summary: Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Mesothelioma (March, 2004)

• Summary: Evaluate the adverse effects and tolerance of Antineoplaston A10 and AS2-1 in these patients.

• Trial offered in: Texas
  (Click the above link for contact information)

---

ALIMTA (pemetrexed) Plus Gemcitabine (Gemzar) for Patients with Malignant Pleural or Peritoneal Mesothelioma who have not had previous chemotherapy (9/19/03)

• Summary: The purposes of this study are to determine: 1) The safety of ALIMTA plus Gemcitabine and any side effects that might be associated with the combination of these two drugs. 2) Whether ALIMTA plus Gemcitabine can help patients with mesothelioma live longer. 3) Whether ALIMTA plus Gemcitabine can make the tumor smaller or disappear, and for how long. 4) To see if patients feel better while taking ALIMTA plus Gemcitabine.

• Trial offered in: Colorado, Florida, Illinois, Maryland, Massachusetts, Michigan, New Mexico, New York, Ohio, Pennsylvania, Wisconsin
  (Click the above link for contact information)

---

Pemetrexed Disodium and Gemcitabine in Treating Patients With Malignant Mesothelioma (September, 2003)

• Summary: Phase II trial to study the effectiveness of combining pemetrexed disodium with gemcitabine in treating patients who have pleural or peritoneal malignant mesothelioma.

• Trial offered in: Ohio
  (Click the above link for contact information)

---

Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma (August, 2003)

• Summary: Phase II trial to study the effectiveness of combining gemcitabine and epirubicin in treating patients who have malignant mesothelioma.

• Trial offered in: Alabama, Arizona, Florida, Illinois, Iowa, Kansas, Louisiana, Michigan, Minnesota, Nebraska, North Dakota, Ohio, Pennsylvania, South Carolina, South Dakota, Wisconsin
  (Click the above link for contact information)

---

Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions (July, 2003)

• Summary: Phase I trial to study the effectiveness of intrapleural BG00001 in treating patients who have malignant pleural mesothelioma or malignantpleural effusions.

• Trial offered in: Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
  (Click the above link for contact information)

---

Salmedix Initiates Phase II Trial For SDX-102. A New Targeted Oncology Agent; Underlying Science to Be Presented at American Association for Cancer Research 2003 Annual Meeting (4/11/03)

• Summary: New multi-center Phase II clinical trial for SDX-102 (L-alanosine), in patients with non-small cell lung cancer, mesothelioma, pancreatic cancer, osteosarcoma and soft tissue sarcoma.

---

Phase II Pilot Study of Surgery and Adjuvant Intracavitary Photodynamic Therapy With Large Diffuser Fibers in Patients With Malignant Mesothelioma (1/26/03)

• Summary: Determine the feasibility of adjuvant photodynamic therapy with large diffuser fibers in patients with malignant mesothelioma undergoing surgery

• Trial offered in: New York
  (Click the above link for contact information)

---

Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma (January, 2003)

• Summary: Phase II trial to study the effectiveness of combining photodynamic therapy with surgery in treating patients who have malignant mesothelioma.

• Trial offered in: New York
  (Click the above link for contact information)

---

Phase I Study of Erlotinib in Patients With Solid Tumors and Hepatic or Renal Dysfunction (11/11/02)

• Summary: Determine the maximum tolerated dose of erlotinib in patients with solid tumors and hepatic or renal dysfunction. Determine the pharmacokinetics of this drug in these patients. (Last Modified 10/2004)

• Trial offered in: California, District of Columbia, Illinois, Iowa, Maryland, New Hampshire, New York, North Carolina, Ohio
  (Click the above link for contact information)

---

Phase I Study of Decitabine-Mediated Induction of Tumor Antigen and Tumor Suppressor Gene Expression in Patients With Unresectable Lung or Esophageal Cancer or Malignant Pleural Mesothelioma (4/30/02)

• Summary: Phase I trial to study the effectiveness of decitabine in treating patients who have unresectable lung or esophageal cancer or malignant mesothelioma of the pleura.

• Trial offered in: Maryland
  (Click the above link for contact information)

---

Phase I Study of SS1(dsFv)-PE38 Immunotoxin in Patients With Advanced Malignancies That Express Mesothelin (4/30/02)

• Summary: Phase I trial to study the effectiveness of immunotoxins in treating patients who have advanced cancer (Last Modified 12/22/2004)

• Trial offered in: Maryland, North Carolina
  (Click the above link for contact information)

• Consent to Particpate -- CLICK HERE

---

Phase II Study of Ecteinascidin 743 in Patients With Unresectable Malignant Mesothelioma (2/14/02)

• Summary: Determine partial and complete response rates in patients with unresectable malignant mesothelioma treated with ecteinascidin 743

• Trial offered in: Massachusetts, New York
  (Click the above link for contact information)

---

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors (March, 2001)

• Summary: Phase II Study of Cisplatin, Doxorubicin, and Tamoxifen (CAT) in Patients With Incurable Soft Tissue Sarcoma, Glioma, Mesothelioma, Hepatoma, Thyroid Cancer, or Adrenal Cancer

• Trial offered in: Canada
  (Click the above link for contact information)

---